Press Releases

Adamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson's Disease and Movement Disorders Congress
Feb 28, 2017

Adamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis at ACTRIMS Forum 2017
Feb 17, 2017

Adamas Outlines Key 2017 Priorities and Highlights 2016 Achievements
Jan 8, 2017

Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
Jan 6, 2017

Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy
Jan 3, 2017

Page: FirstPrevious